Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature

Pellegrino Musto, Potito Rosario Scalzulli, Elisabetta Terruzzi, Fausto Rossini, Pasquale Iacopino, Giuseppe Messina, Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Fiorella D'Auria, Antonietta Falcone, Grazia Sanpaolo, Maria Rosa Valvano, Enrico Maria Pogliani, Fortunato Morabito

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated the effects of a single s.c. injection of peg-filgrastim in 32 patients with multiple myeloma who underwent autologous stem cell transplantation (AuSCT) as first line treatment. For comparison, 32 myeloma patients with similar characteristics and receiving standard daily administration of filgrastim were matched. Overall, there were no statistically significant differences between peg-filgrastim and filgrastim in terms of tolerability, marrow recovery, severity of neutropenia, incidence and duration of febrile neutropenia, documented infections and transfusions. However, some favourable trends or effects in favour of peg-filgrastim were observed. This was confirmed by a review of the published papers about this topic.

Original languageEnglish
Pages (from-to)1487-1493
Number of pages7
JournalLeukemia Research
Volume31
Issue number11
DOIs
Publication statusPublished - Nov 2007

Keywords

  • Autologous transplantation
  • Filgrastim
  • G-CSF
  • Myeloma
  • Neutropenia
  • Peg-filgrastim

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature'. Together they form a unique fingerprint.

Cite this